FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$1.14
+0.09 (+8.57%)
As of Feb 8, 2:09 PM ET ·
Analyst Consensus
Buy
18
Analysts
High
Coverage
Buy 11 61%
Hold 7 39%
Sell 0 0%
Price Target
Analyst Price Target +404.4% upside
Low Target $4.43
Average Target $5.75
High Target $6.69
Current Price $1.14
Current
$1.14
Target
$5.75
$4.43 $5.75 avg $6.69
Scenario Analysis
Bear Case
$4.43
288.6%
Low target
Base Case
$5.75
+404.4%
Avg target
Bull Case
$6.69
+486.8%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$6.09
-81.3% from high
52-Week Low
$2.58
+-55.8% from low
Target vs 52W High
$5.75
-5.6% vs high
Next Earnings Report
Mar 2, 2026 · After Market Close
13d
until earnings
EPS Est: $-0.28
Earnings in 13 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%